Table 1 Characteristics of the included study
Author | Country | Year | Participant (n) In/P | Mean age (year) In/P | Total dose (mg) | Study duration (week) | Study population | Study design | Outcome |
|---|---|---|---|---|---|---|---|---|---|
Zuniga [10] | Mexico | 2018 | 15/15 | 43/45 | 1200 | 12 | IGT | RCT | FBS |
Roshan 5] | Iran | 2018 | 21/22 | 52.76/51.95 | 800 | 8 | MS | RCT | FBS, insulin, HOMA-IR |
Shahmohammadi [14] | Iran | 2017 | 22/22 | 41.36/44.50 | 1000 | 8 | NAFLD | RCT | FBS, insulin, HOMA-IR |
Soga [15] | Japan | 2013 | 18/18 | 36.1/36.1 | 329 | 4 | Healthy | Crossover | FBS |
Wong [17] | Australia | 2014 | 37/37 | 58.5/58.5 | 100 | 12 | BP | Crossover | FBS, insulin, HOMA-IR |
Haidari [16] | Iran | 2017 | 30/34 | 36.1/35.7 | 400 | 8 | Obesity | RCT | FBS, insulin, HOMA-IR |